Comparison of three irradiation ways with Monte Carlo calculation for the feline lymphoma with orthovoltage radiation therapy Authors: Yuki NEMOTO, Yoshinori TANABE, Ryouta ONIZUKA, Munekazu NAKAICHI Published: 2026 ABSTRACT AbstractAlthough orthovoltage radiation therapy remains widely used in veterinary medicine in Japan due to its affordability and operational simplicity, accurate calculation of dose distribution is challenging. Treatment planning varies between practitioners and tends to rely on empirical methods. This study aimed to compare the effects of three different orthovoltage beam directions on dose distribution in feline nasal lymphoma using Monte Carlo simulations. CT images from five clinical cases were analyzed using three irradiation plans: Plan A (beam directed perpendicularly to the hard palate), Plan B (perpendicularly to the nasal bridge), and Plan C (from the oral cavity). Each plan used a 4 × 4 cm field and delivered a 10 Gy dose at 280 kVp. Doses to the tumor, brain, and both eyes were calculated. Mean dose for the tumor did not significantly differ among the three plans. Plan B resulted in significantly higher doses to the ipsilateral eye compared to Plan C, but delivered the lowest brain dose. Depth-dose analysis revealed a peak just above the bone at the beam entrance, followed by a sharp attenuation in all plans. These findings suggest that beam direction substantially affects dose distribution in orthovoltage therapy, particularly for organs at risk including superficial bones and overlying skin. Meticulous planning is essential to ensure sufficient tumor dose coverage while mitigating and distributing adverse effects, especially in complex regions like the feline nasal cavity.Keywords: feline, Monte Carlo, nasal lymphoma, orthovoltage INTRODUCTION Radiation oncology has advanced significantly in veterinary medicine over the past decade. While facilities which use megavoltage (MV) units such as linear accelerators increase, low-energy orthovoltage X-ray machines are still in clinical use, particularly in Japan. According to a 2021 survey, 32 veterinary institutions in Japan were equipped with orthovoltage units [5]. Orthovoltage systems remain valuable in practice due to their accessibility and practicality. They are cost-effective to maintain, relatively simple to operate, and, in Japan, do not require specialized licenses or strict regulated. This makes them a convenient option for facilities without access to MV units and allows timely treatment without patients and owners needing to travel long distances. These advantages contribute to the continued use of orthovoltage therapy in many veterinary clinics. From a physical standpoint, orthovoltage X-rays are characterized by a predominance of photoelectric absorption, which is strongly influenced by tissue density and atomic number. Consequently, bone absorbs more low-energy photons than soft tissue, leading to significantly higher doses in bone and adjacent skin [6]. While this can pose challenges in dose distribution, it also allows high doses to be delivered to tumors near bony structures. Unlike linear accelerators, which enable precise treatment planning and dose calculations for both tumors and organs at risk, orthovoltage units generally lack such advanced capabilities. Therefore, veterinarians must pay close attention to factors that influence dose distribution. This consideration is essential for achieving effective tumor control while minimizing adverse effects. Feline nasal lymphoma is commonly treated with radiation therapy, often combined with chemotherapy [1, 2]. Clinical signs, such as nasal obstruction, typically improve within a few days of irradiation. In urgent cases, orthovoltage therapy can provide prompt relief, even when MV-based treatment planning is unavailable or delayed. We hypothesized that the most appropriate irradiation method would vary depending on tumor location, with beam directions from sites closest to the tumor expected to be most suitable. However, it remains unclear whether the optimal irradiation method can indeed be determined by tumor location. In this study, we aimed to evaluate how different beam directions affect dose distribution in feline nasal lymphoma, using Monte Carlo simulations to estimate doses to the tumor and nearby critical structures. MATERIALS AND METHODS Image selection of the case depended on the tumor location in feline lymphoma Using imaging data from the Yamaguchi University Animal Medical Center, five cases of feline nasal lymphoma were selected based on tumor location, as outlined below: Case 1 –nasal passage; Case 2 −nasopharynx; Case 3 −both nasal passage and nasopharynx; Case 4 −paranasal passage and nasopharynx with orbital and brain involvement; Case 5 −paranasal passage and nasopharynx with orbital, brain, and cranial (dorsal head) involvement (Fig. 1). CT images of the five cases with feline nasal lymphoma: Case 1 −nasal passage; Case 2 −nasopharynx; Case 3 −both nasal passage and nasopharynx; Case 4 −paranasal passage and nasopharynx with orbital and brain involvement; Case 5 −paranasal passage and nasopharynx with orbital, brain, and cranial (dorsal head) involvement. The way of irradiation We compare 3 ways of irradiation direction; Plan A, B and C as follows (Fig. 2). Plan A; the cat was positioned prone and irradiated externally from directly above the head, with the beam directed ventrally and perpendicular to the hard palate. Plan B; the cat was positioned prone and irradiated perpendicularly to the nasal bridge which was defined from the top of the skull to the base of the nose. Plan C; the cat was ventral-dorsal positioned and irradiated from the oral cavity toward the nose. The upper jaw and the edge of the irradiation field was set to be in contact. A 4 cm ×4 cm irradiation field was employed. To facilitate calculation, the dose was set at 10 Gy. Three irradiation approaches used in this study. Plan A; the cat is positioned prone and irradiated externally from directly above the head, with the beam directed ventrally and perpendicular to the hard palate. Plan B; the cat is positioned prone and irradiated perpendicularly to the nasal bridge which was defined from the top of the skull to the base of the nose. Plan C; the cat is ventral-dorsal positioned and irradiated from the oral cavity toward the nose, with the upper jaw set in contact with the edge of the irradiation field. The figure is not drawn to scale and is intended to illustrate the irradiation directions. Dose distribution calculation and profile curve for orthovoltage radiation For dose distribution calculations, Monte Carlo simulations were performed using the EGSnrc-based BEAMnrc (EGSnrc, ver.0.9; National Research Council of Canada, Ottawa, Ontario, Canada) and DOSXYZnrc. MATLAB (MATLAB; The MathWorks, Inc., Natick, MA, USA) was employed to generate input files for EGS and to convert the resulting data into DICOM format [7]. To facilitate the analysis, the generated DICOM files were used in Eclipse Radiotherapy Treatment Planning System (Eclipse, version 16.01.00; Varian Medical Systems, Palo Alto, CA, USA) to evaluate the following parameters; dose for the tumor, dose to the ipsilateral and contralateral eyes, and dose to brain. The minimum, mean and maximum dose of each organ mentioned above, and additionally the maximum dose of the head were assessed. To clarify the characteristics of orthovoltage X-ray, depth dose profiles were analyzed to determine the percentage depth dose. For this analysis, the beam axis of the irradiation field was used, with the skin surface defined as 100% of the dose. Additionally, anatomical structures traversed by the beam were examined to understand tissue composition along the beam path. The orthovoltage unit is composed of an X-ray target (rhenium–tungsten, 2.0 cm, target angle 22°), an X-ray window (beryllium, 4.0 mm), an aluminum filter (1.0 mm), a combined aluminum–copper filter (1.0 mm each), a primary collimator (lead, 4.3 cm), a monitor chamber, and a mirror. The beam characteristics include a tube potential of 280 kVp, a half-value layer of 3.26 mm copper. The modeling results for orthovoltage X-rays simulated with the EGSnrc-based BEAMnrc were evaluated by comparing the calculated and measured percentage depth doses (PDDs). The PDDs were measured using farmer-type dosimeters (PTW 30,013, PTW-Freiburg, Germany) and a 30 cm × 30 cm tough water phantom (Kyoto Kagaku Co., Ltd., Kyoto, Japan) at six depths (1, 2, 3, 4, 5, and 8 cm). In this evaluation, the difference between calculated and measured PDDs was less than 2.0% at all depths, consistent with our previous study [4]. Data were analyzed by ANOVA, and differences between groups were assessed using Tukey’s multiple comparisons test using JMP statistics software, version 18 (JMP Statistical Discovery LLC, Cary, NC, USA). Statistical significance was set P<0.05. RESULTS Tumor volume (cm3) and the minimum, mean, and maximum percentages of the prescription dose delivered to the tumor for each irradiation plan are shown in Table 1. No significant differences were observed in the minimum or mean dose relative to the prescription dose among plans A, B and C. However, the maximum dose was significantly higher in plan B compared with plan C (P=0.0066). In addition, dose volume histograms (DVHs) of the tumor in three plans in each case are presented in Fig. 3. The percentages of the prescription dose for eyes including tumor side and another side were shown in Fig. 4A and 4B, respectively. As mentioned already, Case1 was excluded because the location of the tumor was both passages, in the middle of the eyes. The median percentages of the prescription dose for the tumor side, in Case 2, 35.84, 57.72, 43.4%, respectively. In Case 3, 38.5, 61.26, 33.37%, respectively. In Case 4, 47.79, 64.11, 11.16, respectively. In Case 5, 28.92, 43.21, 36.07%, respectively. For the dose for another side of the eye as follows; in Case 2, 49.17, 63.98, 56. 51%, respectively. In Case 3, 40.93 54.45 60.88%, respectively. In Case 4, 18.94, 26.54, 64.99%, respectively. In Case 5, 4.57 6.1, 6.26%, respectively. Significant differences were detected in tumor side eye (P=0.0203), particularly between the Plan B and C (P=0.0195), while no significant differences were not observed among Plan A, B and C on the healthy side (P=0.5874). The percentages of the prescription dose for brain were shown in Fig. 5. The median percentages of the dose in Case 1, 7.73, 4.77, 7.25%, respectively. In Case 2, 16.67, 6.71, 32.79%, respectively. In Case 3, 43.34, 6.52, 30.51%, respectively. In Case 4, 19.68, 5.93, 9.16%, respectively. In Case 5, 14.06, 8.12, 21.54%, respectively. The brain dose of Plan B tends to decrease compared to other plans, but there were no differences significantly (P=0.0914). The percentages of the dose for the maximum in each plan for case1 was 157.98, 159.77, 143.2%, respectively. For case 2 was 142.45, 158.02, 149.11%, respectively. For case 3, 146.6, 155.65, 147.31%, respectively. For case 4 was 160.75, 160.85, 143.43%, respectively. For case 5, 146.99, 153.92, 134.15%, respectively. There were significant differences (P=0.0087) among three plans. Moreover, the dose of Plan C was significantly lower than Plan B (P=0.0066). The dose percentages as a function of depth along the beam axis were evaluated for each case (Fig. 6). In all cases, the maximum dose was observed just above the bone at the entrance of the irradiation field. A gradual attenuation was seen in the tumor region across all plans, following an initial build-up in the first bone layer. Table 1.Tumor volume (cm3) and dose distribution (minimum, mean, maximum percentages of the prescription dose) for each planCaseTumor volumePlan APlan BPlan CMinMeanMaxMinMeanMaxMinMeanMax111.137.4096.54157.9848.00103.26159.7710.4694.17143.2022.950.8697.99142.4552.71107.06158.0250.79107.29149.11320.364.5673.23146.6069.8697.97155.6542.1890.79147.31420.27.8694.48160.757.9998.32160.850.1085.40143.43542.27.8976.02146.994.2071.68153.928.4566.14134.15 Tumor volume (cm3) and dose distribution (minimum, mean, maximum percentages of the prescription dose) for each plan Dose volume histograms (DVHs) of the tumor for three plans in each case: Plan A (red), Plan B (blue), and Plan C (green). The Y-axis represents the percentage of the total volume, and the X-axis represents the absolute dose (cGy). The median percentages of the dose for eyes including tumor side and another side for each plan are summarized, respectively. In the box-and-whisker plots, the upper and lower whiskers indicate the maximum and minimum values, respectively. The “x” symbol denotes the mean. The bottom edge of the box represents the first quartile, the line within the box indicates the median (second quartile), and the top edge of the box represents the third quartile. The percentages of the prescription dose for brain in Plan A, B and C. In the box-and-whisker plots, the upper and lower whiskers indicate the maximum and minimum values, respectively. The “x” symbol denotes the mean. The bottom edge of the box represents the first quartile, the line within the box indicates the median (second quartile), and the top edge of the box represents the third quartile. Dose percentages as a function of depth along the beam axis for each case. A gradual attenuation is seen in the tumor region, following an initial build-up in the first bone layer. DISCUSSION Interestingly, the mean dose to the tumor did not differ significantly among the three beam directions evaluated in this study. It was initially hypothesized that optimal beam directions could be determined based on tumor location. For example, in Case 2, where the tumor was located in the nasopharynx, it was hypothesized that Plan C would deliver the optimal dose due to the proximity of the X-ray entry point and the potential dual build-up effect from surrounding bony structures. However, no substantial differences in tumor dose were observed among the irradiation methods (Fig. 7), likely due to the limited penetration capability of orthovoltage X-rays caused by their low energy. In Case 4, the characteristics of orthovoltage radiation were particularly evident. The dose peaked at the bone surface due to the initial build-up, but the dose within the tumor remained lower than the prescribed level, illustrating the challenge of delivering sufficient radiation to deep-seated targets. Dose percentages as a function of depth along the beam axis in Case 2, where the tumor was located in the nasopharynx. The corresponding tissue structures at each depth are also indicated in the graph. Dose distributions of each plan are also shown. A; Air, B; Bone, Br: Brain, T; Tumor, S; Soft tissue, W; Water (discharge). The dose to the ipsilateral eye tended to be highest in Plan B, while the dose to the brain was lowest in the same plan. This reflects the beam path: in Plan B, the X-ray beam avoids much of the cranial contents, thereby reducing brain exposure but increasing the risk of ocular irradiation. Although this study did not assess protective measures, previous research indicates that lead shielding approximately 2 mm thick can effectively block orthovoltage X-rays [4]. Thus, lead shielding may be useful to protect the eyes during Plan B irradiation. In contrast, in Plans A and C, the beam traversed the brain and was directly influenced by the parietal bone. Because shielding the brain is impractical when irradiating the nasal cavity, careful evaluation of tumor location and beam field is essential when using these approaches. Depth-dose analysis revealed that the maximum dose tended to occurred just above the bone at the beam entrance, with gradual attenuation in the tumor region. This confirms the known behavior of orthovoltage radiation, where a build-up effect occurs at high-density tissues due to photoelectric absorption, followed by rapid fall-off, which limits deep penetration. In our study, maximum doses ranged from 112% to 181%. Compared with the skin surface dose, the dose at the proximal bone near the beam entrance increased to nearly 190% in one case as shown in Fig. 6. Previous work reported that orthovoltage beams can deliver up to 170% dose in bone after passing through 0.5 cm of bone followed by 1 cm of water-equivalent tissue in a canine virtual phantom [4]. The risk of late bone complications with orthovoltage therapy, such as osteoradionecrosis and radiation-induced bone tumors, has been reported to be as high as 11% in dogs [3]. Other studies found that osteoradionecrosis tends to occur at sites of nasal or oral tumors, possibly due to pre-existing bone invasion [8, 9]. Although data on such adverse effects in cats are limited, veterinarians should be aware of the potential for similar complications, especially when the tumor involves bone. A major limitation of this study is the small number of cases. Furthermore, dose distribution may be sensitive to slight shifts in the isocenter, as minor changes in bone thickness or air cavity structure within the nasal cavity can alter the dose profile. The results of this study differ according to the specifications of the orthovoltage equipment and are not generalizable to all orthovoltage systems. In conclusion, Plan B tended to deliver a higher dose to the tumor; however, considering the risk of ocular side effects, varying the irradiation angle across treatment sessions may enhance tumor control while reducing toxicity. Alternating beam directions may also help minimize dose accumulation in the same bony region and thereby lower the risk of adverse events. Based on these findings, orthovoltage radiation may achieve high tumor doses when the lesion is surrounded by bone, but it also increases the dose to the bone and adjacent skin. Ultimately, accurate assessment of tumor and normal tissue doses necessitates referral to a facility equipped with megavoltage radiation therapy, or the owner should be informed that orthovoltage techniques are inherently limited in providing reliable dose calculations and toxicity evaluation. Conflicts of Interest None of the authors have any financial conflicts of interest in the present study. REFERENCES